CA-DNSC/DRUPA-2016
31.5.2016 15:09:45 CEST | Business Wire | Press release
Diversified Nano Solutions Corporation (DNSC) will be exhibiting digital INKS unlimited at Drupa “Touch the Future” 2016, May 31 – June 10, 2016, in Düsseldorf, Germany, at Halle 2-B05
Based in San Diego, California, with manufacturing facilities in the US and Europe, DNSC specializes in developing and manufacturing digital inks, nano materials, and fluids for high-resolution, high-performance digital inkjet printing. DNSC provides unique ink development services, research, and turn-key ink supply and fulfillment solutions reaching end users, resellers and, printer manufacturers worldwide. DNSC has developed an extensive product line under the x-nano™ brand, providing a range of solutions including high-quality, low-cost black & color dye inks (Value-Series), pigment inks (Elite Series), special ultra-fast dry inks (S-Series), magnetic MICR inks (K-Series), invisible fluorescent color (RGB) inks, infrared-absorbing inks (I-Series), and special inks for food grade, textile, and special effect applications (F-, T-, and X-Series). The company’s digital inks target dot-on-demand inkjet applications based on thermal and piezo print heads using aqueous, oil, energy-curable (UV/LED), and eco-solvent based inks.
DNSC offers a wide array of inkjet inks at unprecedented low cost supporting direct mail, transactional, transpromo, books, catalogs/magazines, ticket, tags, labels, and graphics printing applications. DNSC is uniquely positioned to help users create differentiated, high-value output through personalization using x-nano™ special effect inks such as magnetic (MICR), invisible fluorescent, spot color, and security inks for thermal & piezo digital inkjet platforms.
The company supports its ink offerings with accessories to facilitate and aid x-nano™ ink use and applications. These include specialty substrates, UV display lights, INKVERSE™ “Infinite Ink Infuser” – a revolutionary and cost-effective way to adopt and deliver digital inks to existing and new inkjet systems via a continuous delivery ink supply system, and TransChrome™ – an Invisible Color Image Generator to transform CMYK into UV fluorescent RGB output, and more.
At Drupa 2016, DNSC introduces X-Series, a new family of pigment powders and dispersions to serve as base components for custom development and production of ink, paint, paste, dispersion, gel, cream, and powder. These special effect base materials photo-luminesce, fluoresce, absorb IR, and change color with light or heat. X-Series materials have highly customizable properties that allow for various exceptionally unique market applications associated with digital and non-digital printing applications.
DNSC will be showcasing its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial, and industrial inkjet space.
Visit Halle 2-B05 and discover DNSC digital INKS unlimited!
View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005263/en/
Contact:
Diversified Nano Solutions Corporation
Kimberly Villwock
US:
+1.858.924.1005
EU: +41.41 874 08 50
kimberlyv@diversifiednano.com
info@diversifiednano.com
www.diversifiednano.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom